Georgia is currently home to 1952 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
NCT04939116
Recruiting
The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2022
Locations: Davita Clinical Research, Columbus, Georgia
Conditions: Glomerular Disease, Proteinuria
Register for Updates
Home OCT Fluid Visualization Agreement Study
NCT04907409
Recruiting
This is a single arm study of home monitoring with the NVHO for 5 weeks with office visits at enrollment, Week 1 and Week 5 (Exit Visit) and, when applicable, Interim Visit(s) triggered by ongoing review by the Reading Center. The study will enroll subjects diagnosed with NV-AMD in at least one eye with attention to the proportion of eyes with IRF and/or SRF. The enrolled eligible subjects will be instructed to self-image the study eye(s) once daily for 5 weeks using a NVHO device at home with s... Read More
Gender:
All
Ages:
55 years and above
Trial Updated:
03/08/2022
Locations: Georgia Retina, Marietta, Georgia
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
NCT02061436
Recruiting
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly being performed in patients with advanced coronary artery disease, but there is limited information on the techniques utilized and the procedural outcomes. The goal of this multicenter, investigator initiated registry is to collect information on treatment strategies and outcomes of consecutive patients undergoing CTO PCI among various participating centers. The information collected will be used to deter... Read More
Gender:
All
Ages:
All
Trial Updated:
03/08/2022
Locations: Piedmont Heart Institute, Atlanta, Georgia
Conditions: Coronary Artery Disease
Register for Updates
KRT-232 and TKI Study in Chronic Myeloid Leukemia
NCT04835584
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/04/2022
Locations: Georgia Cancer Center at Augusta University, Augusta, Georgia
Conditions: Chronic Myeloid Leukemia
Register for Updates
Health and Resilience Projects: Foundations
NCT05253235
Recruiting
The Health and Resilience Project (HARP): Foundations is investigating the efficacy of the Strong African American Families (SAAF) intervention in promoting the health and well being of African American adolescents. Youth age 10-13 and their primary caregivers are randomly assigned to receive SAAF or to a control group. Participants complete baseline and follow-up measures regarding vulnerability to substance use based on a neuroimmune model of stress coping.
Gender:
All
Ages:
Between 10 years and 13 years
Trial Updated:
02/14/2022
Locations: Center for Family Research, Athens, Georgia
Conditions: Substance Use
Register for Updates
Compliance With Enhanced Recovery After Surgery Protocol (ERAS) in Surgical Patients
NCT03968666
Recruiting
The concept of "enhanced recovery" was introduced by European anesthesiologists and surgeons who challenged traditional clinical practices involved in peri-operative care in 1990s. The goal of enhanced recovery programs (ERP) is to maintain normal physiology thereby decreasing complications. It focuses on peri-operative optimization of patient care. It was originally created for open colorectal surgeries but now has shown benefit in various surgical specialities including thoracic surgery, vascu... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/14/2022
Locations: Augusta University, Augusta, Georgia
Conditions: Surgery, Anesthesia
Register for Updates
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
NCT03545607
Recruiting
A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2022
Locations: Athersys Investigational Site 103, Augusta, Georgia
Conditions: Ischemic Stroke
Register for Updates
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
NCT02675946
Recruiting
This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose Expansion Phase in GI tumors and Roll-over Cohort of CGX1321 and pembrolizumab in subjects who have progressed on single agent CGX1321 and Phase 1b consisting of CGX1321 in combination with pembrolizumab in colorectal tumors and CGX1321 in combination with encorafenib + cetuximab in BRAFV600E mutated colorectal tumors. Both... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: University Cancer & Blood Center (QCCA), Athens, Georgia
Conditions: Solid Tumors, GI Cancer
Register for Updates
Prediction of Outcomes After Surgery for Unruptured Intracranial Aneurysms
NCT04819074
Recruiting
Accurate preoperative identification of patients at high risk for adverse outcomes would be clinically advantageous, as it would allow enhanced resource preparation, better surgical decision-making, enhanced patient education and informed consent, and potentially even modification of certain modifiable risk factors. The aim of the Prediction of adverse events after microsurgery for intracranial unruptured aneurysms (PRAEMIUM) study is therefore to develop and externally validate a clinically app... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2021
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Aneurysm, Brain
Register for Updates
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
NCT05027997
Recruiting
This study is designed to assess the safety and tolerability of dipraglurant in patients with blepharospasm (BSP) (randomized 1:1:1 to receive dipraglurant 50 mg, 100 mg or placebo) and explore the efficacy of 50 mg and 100 mg immediate release tablets (versus placebo) on the severity and frequency of BSP signs and symptoms using objective measures, clinical ratings and patient reported outcomes.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
11/01/2021
Locations: Emory University, Atlanta, Georgia
Conditions: Blepharospasm, Dystonia
Register for Updates
Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments
NCT05110963
Recruiting
Retention in care and persistent adherence to antiretroviral therapy are necessary for the successful treatment of HIV infection. HIV-related stigma is a known impediment to the care and health outcomes of people living with HIV. The proposed study will test theory-based interventions designed to manage HIV stigma in order to improve care retention and medication adherence in communities with high-levels of HIV-related stigma.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/28/2021
Locations: University of Connecticut Field Site, Atlanta, Georgia
Conditions: HIV I Infection
Register for Updates
HIV Treatment Adherence Dose Determination Trial
NCT04577313
Recruiting
The proposed research will conduct the first dose-determination trial to find the optimal number of behavioral counseling sessions (dose) needed to achieve and sustain optimal HIV treatment adherence. The results of this study will determine how much intervention is needed for whom and at what cost to guide health policy and implementation of behavioral interventions designed to improve durable viral suppression.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/13/2021
Locations: University of Connecticut Field Site, Atlanta, Georgia
Conditions: HIV Infections
Register for Updates